Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials by Raffi, Franҫois et al.
Dolutegravir efficacy at 48 weeks in key subgroups of
treatment-naive HIV-infected individuals in three
randomized trials
François Raffia, Anita Rachlisb, Cynthia Brinsonc, Keikawus Arastehd,
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provided it is propeObjectives: Dolutegravir (DTG) has been studied in three trials in HIV treatment-naive
participants, showing noninferiority compared with raltegravir (RAL), and superiority
compared with efavirenz and ritonavir-boosted darunavir. We explored factors that
predicted treatment success, the consistency of observed treatment differences across
subgroups and the impact of NRTI backbone on treatment outcome.
Design: Retrospective exploratory analyses of data from three large, randomized,
international comparative trials: SPRING-2, SINGLE, and FLAMINGO.
Methods: We examined the efficacy of DTG in HIV-infected participants with respect
to relevant demographic and HIV-1-related baseline characteristics using the primary
efficacy endpoint from the studies (FDA snapshot) and secondary endpoints that
examine specific elements of treatment response. Regression models were used to
analyze pooled data from all three studies.
Results: Snapshot response was affected by age, hepatitis co-infection, HIV risk factor,
baseline CD4þ cell count, and HIV-1 RNA and by third agent. Differences between
DTG and other third agents were generally consistent across these subgroups. There was
no evidence of a difference in snapshot response between abacavir/lamivudine (ABC/
3TC) and tenofovir/emtricitabine (TDF/FTC) overall [ABC/3TC 86%, TDF/FTC 85%,
difference 1.1%, confidence interval (CI) 1.8, 4.0 percentage points, P¼0.61] or at
high viral loads (difference 2.5, 95% CI 8.9, 3.8 percentage points, P¼0.42).
Conclusions: DTG is a once-daily, unboosted integrase inhibitor that is effective in
combination with either ABC/3TC or TDF/FTC for first-line antiretroviral therapy in HIV-
positive individuals with a variety of baseline characteristics.
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Once-daily (q.d.) dolutegravir (DTG) 50 mg in combi-
nation with abacavir/lamivudine (ABC/3TC) or teno-
fovir/emtricitabine (TDF/FTC) is the most recent
addition to the list of regimens recommended for
treatment-naive HIV-positive individuals [1].
Individual characteristics such as sex, age, race, chronic
hepatitis co-infection, and HIV stage, as well as baseline
CD4þ cell counts and HIV-1 RNA, can influence the
efficacy and tolerability of antiretroviral therapy (ART)
[2–5]. We examined the efficacy of DTG across baseline
characteristics in HIV-infected individuals participating
in three phase III studies [6–9]. In particular, we further
examined the relationship between baseline viral load,
nucleoside reverse transcriptase inhibitor (NRTI) back-
bone, and virologic response.Methods
Detailed methodology for SPRING-2 (ClinicalTrials.gov
identifier: NCT01227824), SINGLE (NCT01263015),
and FLAMINGO (NCT01449929) has been reported
previously [6–8]. In brief, SPRING-2 (N¼ 822)
compared DTG to raltegravir (RAL), SINGLE
(N¼ 833) compared DTG þ ABC/3TC to efavirenz
(EFV)/TDF/FTC, and FLAMINGO (N¼ 484) com-
pared DTG to darunavir/ritonavir (DRV/r). SPRING-2
and FLAMINGO used investigator-selected nucleosides
(ABC/3TC or TDF/FTC). SPRING-2 and SINGLE
were double-blind studies, and virologic failure was
defined as confirmed HIV-1 RNA at least 50 copies/ml
on or after week 24; FLAMINGO was open-label and its
threshold for virologic failure was plasma HIV-1 RNA
above 200 copies/ml.
The primary endpoint for each study was the proportion
of individuals with plasma HIV-1 RNA below 50 copies/
ml at week 48, as codified by the Food and Drug
Administration snapshot algorithm [10].
Each study also examined time to treatment or to









Difference (CIa) 1.5 (–2.1, 5.1)
CI, confidence interval; DTG, dolutegravir.
aDifference based on Kaplan–Meier estimates; CI based on Greenwood’sERDF). The TRDF analysis calculated the time to
protocol-defined virologic failure or discontinuation at
any time for treatment-related reasons, such as drug-
related adverse events, protocol-defined safety stopping
criteria, or lack of efficacy. Participants who discontinued
for reasons unrelated to treatment were censored at the
time of discontinuation. In the ERDF analysis, censoring
applied to discontinuations for reasons unrelated to
efficacy. Analyses of these secondary endpoints allowed us
to assess the impact of each risk factor on the three
constituents of the snapshot response (virologic response,
tolerability, and administrative dropout).
We examined consistency of primary endpoint treatment
differences within each study according to baseline HIV-1
viral load and NRTI backbone, CD4þ cell count, sex,
baseline age (<36 or 36 years), and race (white or
African American/African heritage). We explored the
impact of subgroups in a pooled dataset using multivariate
binomial regression. For any factor associated with
prognosis, we also used the regression model to test
whether the effect of DTG was consistent across different
levels of that factor.
Cox regression [11] was used to explore the effect of each
factor on time to TRDF or ERDF.
All regression models were chosen using stepwise
selection with Akaike’s information criterion (AIC) [12].Results
The analysis included data for all 2139 participants from
the primary analyses of the individual studies. Baseline
characteristics and primary efficacy results have been
reported previously [6–8]. Table 1 presents the overall
efficacy results (TRDF and ERDF rates) at week 48. In
SINGLE and FLAMINGO studies, there was a
statistically significant difference in the primary endpoint
in favor of DTG [7,8]. A statistically significant difference
persisted for the proportion with TRDF in the SINGLE
study. There was no significant difference between third
agents in the proportion with ERDF.phase III studies of dolutegravir.
SINGLE (N¼833) FLAMINGO (N¼484)
391/414 (94%) 238/242 (98%)
365/419 (87%) 233/242 (96%)
7.7 (3.6, 11.7) 2.4 (–0.7, 5.4)
396/414 (95%) 240/242 (99%)
402/419 (95%) 240/242 (99%)
0.2 (–2.9, 3.3) 0.2 (–1.7, 2.1)
formula.
Dolutegravir phase III subgroup analyses Raffi et al. 169Figure 1a presents the snapshot response rates in each of
the subgroups. The response rates for the DTG arms were
generally consistent within each subgroup. For example,
the response rates for women receiving DTG were
between 84 and 85% in the three studies.
In each study, treatment differences between DTG and
the comparator were generally consistent across sub-
groups. For example, in the SPRING-2 study, response
rates for DTG and RAL were similar overall, as well as in
both men and women; in the SINGLE study, the
treatment difference favored DTG overall, as well as in
both men and women.
The only notable case of inconsistency in treatment
effects across subgroups was in the subgroup of
participants in the FLAMINGO study with high viral
load at baseline (n¼ 61 in each arm). In this subgroup,
there was a particularly pronounced treatment difference.
This was driven both by a higher response rate for those
receiving DTG within this study subgroup (compared
with the other two trials: 93% versus 83 and 82% in
SINGLE and SPRING-2 study, respectively) and a lower
response rate for those receiving the comparator (70%
receiving DRV/r in FLAMINGO versus 76% receiving
EFV/TDF/FTC in SINGLE and 75% receiving RAL in
SPRING-2 study). Four participants in the FLAMINGO
study experienced ERDF, two of whom had a baseline
viral load above100 000 copies/ml: one of these indivi-
duals received DTG and the other received DRV/r.
Response in subgroups defined by sex or race should be
interpreted with caution due to the small number of
participants who were women or non-white. In each of
these subgroups, confidence intervals (CIs) around
treatment differences were wider than 12 percentage
points. A similar caveat applies to the interpretation of the
differences seen in small subgroups defined by the
combination of NRTI backbone and baseline viral load
(Fig. 1b).
Regression analyses of the snapshot response, and time to
TRDF and to ERDF used pooled data from all three
studies and are presented in Table 2. The snapshot
regression analyses were consistent with the primary
analyses of the studies. These analyses revealed the
significant effects of the treatment arm: DTG-treated
individuals responded comparably with RAL-treated
individuals, but significantly better when compared with
DRV/r and EFV-treated individuals. Baseline viral load,
CD4þ cell count, age, race, risk factor, and hepatitis co-
infection were also significantly prognostic of response in
these multivariate models (Table 2).
There was statistically significant evidence of a larger
difference between DTG and comparator among
participants with a higher viral load. This was attributable
to the previously discussed finding in the FLAMINGOstudy among participants with high baseline viral load.
There was no other evidence of inconsistency in snapshot
treatment differences across other subgroups.
Pooled analyses revealed no significant difference in
snapshot response between ABC/3TC and TDF/FTC
overall (ABC/3TC 86%, TDF/FTC 85%, difference
1.1%, 95% CI1.8, 4.0 percentage points, P¼ 0.61) or at
high viral loads (difference 2.5, 95% CI 8.9, 3.8
percentage points, P¼ 0.42).
Baseline plasma HIV-1 RNA, CD4þ cell count, third
agent (EFVonly), and study were associated with time to
TRDF. Treatment differences on this endpoint were not
consistent across subgroups defined by baseline CD4þ cell
count or HIV-1 RNA (P value for interaction <0.05).
The Supplemental Digital Content (http://links.lww.-
com/QAD/A601) shows Kaplan–Meier plots of time to
TRDF by treatment and these factors. The difference in
TRDF between DTG versus EFV was most pronounced
in participants with high baseline CD4þ cell count and
less pronounced in participants with low baseline CD4þ
cell count. There was no suggestion of inconsistency
across viral load strata after allowance for the CD4þ cell
count effect.
There was no significant difference in time to TRDF
between the NRTI backbones overall (hazard ratio 0.92,
95% CI 0.57–1.49, P¼ 0.74) or at high (hazard ratio
1.07, 95% CI 0.58–2.0, P¼ 0.83) baseline plasma HIV-1
RNA.
Participants with a baseline HIV-1 RNA above
100 000 copies/ml or a baseline CD4þ cell count below
200 cells/ml were at significantly greater risk of ERDF
over time. Participants in the FLAMINGO study were
less likely to experience virologic failure, largely due to
the different virologic failure definition in this study.
There was no suggestion of inconsistency of third-agent
differences in time to ERDF.
There was no significant difference in the likelihood of
ERDF for participants receiving ABC/3TC compared
with TDF/FTC overall (hazard ratio 0.90, 95% CI 0.58–
1.38, P¼ 0.63) or at high (hazard ratio 0.95, 95% CI
0.55–1.65, P¼ 0.86) baseline HIV-1 RNA. This
comparison of the NRTIs was supported by Kaplan–
Meier curves of time to ERDF stratified by baseline viral
load and NRTI (Fig. 2).Discussion
Although three individual randomized studies have
demonstrated high efficacy and favorable benefit–risk
for DTG compared to RAL, EFV, or DRV/r for first-line
ART, the sample size of these studies does not allow
examination of individual characteristics that might affect
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Fig. 1. Snapshot response rates by subgroup in each study; (a) univariate and (b) bivariate summaries by baseline viral load and
NRTI backbone. Specific subgroups for male and white participants are omitted from (a): these subgroups comprised more than
75% of the study populations, and their results mirrored those in the overall population. ABC/3TC, abacavir/lamivudine; DTG,
dolutegravir; NRTI, nucleoside reverse transcriptase inhibitor; TDF/FTC, tenofovir/emtricitabine.











































































































































































































































































































































































































































































































































































































































































































































































































































































































































Week 48Week 32 Week 24 Week 12 Day 0 
ABC/3TC, ≤100k 12/293/3665/42/624 3/33/635 0/23/648 0/0/671 
ABC/3TC, >100k 21/84/13017/15/203 11/13/211 0/8/227 0/0/235 
TDF/FTC, ≤100k 19/382/45010/65/776 6/59/786 0/38/813 0/0/851 
TDF/FTC, >100k 31/158/19326/34/322 15/29/338 0/22/360 0/0/382 
Fig. 2. Kaplan–Meier estimates of time to ERDF stratified by NRTI backbone and baseline plasma HIV-1 RNA (VL) (log10 copies/
ml). The number of events, censored events, and patients at selected intervals are noted below the graph. ABC/3TC, abacavir/
lamivudine; IQR, interquartile range of baseline viral load; NRTI, nucleoside reverse transcriptase inhibitor; TDF/FTC, tenofovir/
emtricitabine; VL, viral load.virologic response or treatment outcome. By pooling data
from more than 2000 clinical trial participants in these
studies, we provide new and relevant clinical information
on the efficacy of DTG across various treatment
subgroups, including backbone NRTI.
The results of these exploratory subgroup analyses support
the primary results from the three phase III studies –
SPRING-2, SINGLE, and FLAMINGO [6–8].
Treatment differences were largely consistent across
subgroups. There was no subgroup in which we observed
a response rate for DTG that was significantly lower than
that of another third agent. Some significant differences in
favor of DTG were more pronounced in certain
subgroups (e.g. high viral load in FLAMINGO study
for the primary endpoint or TRDF for high CD4þ cell
count in SINGLE study) and, by corollary, attenuated in
complementary subgroups (low viral load in FLA-
MINGO study or low CD4þ cell count in SINGLE
study). Since these findings were not observed consist-
ently across studies or across endpoints within studies,
they do not alter the overall conclusions about efficacydrawn from the studies. The efficacy of DTG versus
standard-of-care comparators at week 48 was consistent
in subgroups defined by sex, race, and age.
There was some variability in response that applied
equally across all treatments. The principal prognostic
factors for snapshot response (after third agent) were
baseline plasma HIV-1 RNA, baseline CD4þ cell count,
age, race, risk factor, and hepatitis co-infection. The
effect of the principal factors was not always significant for
endpoints that focused on components of the snapshot
response. For example, only baseline viral load, CD4þ cell
count, and study were predictive of both the time to
TRDF endpoint and the purely virologic time to ERDF
endpoint. The third agent was associated with time to
TRDF, but not to ERDF.
Some studies have shown an association between NRTI
backbone and probability of virologic response, including
individuals with high baseline viral load [13]. This finding
has not been uniformly replicated [14]. The analysis
provided herein consisting of pooled data from three
studies provides new data comparing ABC/3TC with
Dolutegravir phase III subgroup analyses Raffi et al. 173TDF/FTC. This analysis showed no difference between
the two NRTI backbones when coupled with the third
agents studied in the SPRING-2, SINGLE, and
FLAMINGO studies at low or high viral loads for the
primary snapshot endpoint, the TRDF endpoint, and for
a pure virologic ERDF endpoint. It is important to note
that this comparison was not randomized. Therefore,
biases cannot be excluded, in particular, channeling
bias, whereby investigator preference for TDF/FTC in
individuals with very high viral load could leave the
hardest-to-treat participants on that NRTI backbone.
However, it is worth noting that analyses of the
distribution of baseline viral load by NRTI and viral
load subgroup (Fig. 2) do not suggest that among
participants with high baseline viral loads, the subgroup
taking TDF/FTC had a greater proportion of participants
with extremely high baseline viral loads than the
subgroup taking ABC/3TC.
The survival analyses presented herein have statistical
limitations: the exact time of virologic failure or loss to
follow-up is not known precisely; the proportionality of
hazards for Cox models cannot be assessed with great
power across a number of strata when there are limited
failures observed, largely, at a small number of scheduled
visits; and the classification of individuals who drop out
for reasons unrelated to treatment is problematic.
Analyses of the snapshot endpoint share the last problem
and ignore the time at which failure occurred. Our
statistical models each make different statistical assump-
tions, but the main findings of this analysis were robust to
the methods used.
In conclusion, the efficacy findings from the individual
studies were largely consistent across subgroups, including
baseline HIV-1 RNA, CD4þ cell count, sex, age, and
race. Exploratory analyses did not suggest a difference in
response between the NRTI backbones used in these
studies. DTG is a q.d. integrase inhibitor without the
need for pharmacokinetic boosting that can be used
effectively in combination with either TDF/FTC or
ABC/3TC in a wide variety of HIV-positive individuals
for first-line ART.Acknowledgements
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